Granted Patent
B2
US 12,527,865 · App. 17/901,391 · Granted Jan 20, 2026
haNK cetuximab combinations and methods
Assignee:
NantCell, Inc.
A61K39/39558A61K31/704A61K40/15A61K40/4205A61K40/4242A61K40/4253A61K40/4257A61K40/4266A61P31/00A61P35/00C07K16/2818C07K16/2827C07K16/2863A61K2039/507A61K2039/523A61K2039/5256A61K2039/545A61K2039/852A61K2239/31A61K2239/38A61K2239/54
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Contemplated cancer therapies comprise co-administration of aldoxorubicin with an immune therapeutic composition that preferably comprises a vaccine component and a cytotoxic cell component.
Claims (17)
1 . A method of treating a patient having a tumor, comprising:
providing an immune therapeutic composition comprising (a) a vaccine component comprising a vector comprising a recombinant nucleic acid encoding at least one of brachyury, MUC1, and CEA, (b) cetuximab, (c) a cytotoxic cell component comprising at least one of a haNK cell, a taNK cell, and a T cell, wherein the haNK cell, the taNK cell or the T cell is genetically engineered to express a high affinity CD16 variant and/or a chimeric antigen receptor, and (d) ALT803;
providing a chemotherapeutic composition comprising aldoxorubicin; and
administering the immune therapeutic composition and the chemotherapeutic composition in a dose and schedule sufficient to treat the tumor.
2 . The method of claim 1 , further comprising administering an antibody to the patient or a protein that interferes with or down-regulates checkpoint inhibition.
3 . The method of claim 2 , wherein the antibody is coupled to the cytotoxic cell component.
4 . The method of claim 2 , wherein the antibody specifically binds to at least one of a growth factor receptor, a blood vessel growth receptor, an immune checkpoint inhibitor, a tumor associated antigen, a tumor specific antigen, or a tumor- and patient-specific neoepitope.
5 . The method of claim 2 , wherein the protein that interferes with or down-regulates checkpoint inhibition is an antibody or an antagonist of CTLA-4, PD-1, TIM1 receptor, 2B4, or CD160.
6 . The method of claim 1 , wherein the tumor is a solid tumor.
7 . The method of claim 1 , wherein the vaccine component and the cytotoxic cell component are separately administered by at least one day.
8 . The method of claim 1 , wherein the patient has a medical history of at least one of previous platinum-based chemotherapy and anti-PD-1/PD-L1 therapy.
9 . The method of claim 1 , further comprising determining a molecular profile of the patient, wherein the molecular profile comprises an HER2 expression level or a RAS mutation status.
10 . The method of claim 1 , wherein the tumor is metastatic Squamous Cell Carcinoma (SCC).
11 . The method of claim 1 , wherein the haNK cell is a NK-92 derivative cell with a high affinity CD16 variant or V158 variant.
12 . The method of claim 1 , further comprising a vaccine component comprising yeast vectors expressing brachyury, Ras, and CEA.
13 . The method of claim 1 , wherein the vaccine component comprises a nanoparticle as a core.
14 . The method of claim 1 , wherein the vector is a mRNA vector.
Assignments (2)
NUNC PRO TUNC ASSIGNMENT
Recorded May 5, 2025
From: SOON-SHIONG, PATRICK
To: NANTCELL, INC.
Reel/Frame 071025/0848 →
SECURITY INTEREST
Recorded Jan 2, 2024
From: IMMUNITYBIO, INC.; NANTCELL, INC.; RECEPTOME, INC.; VBC HOLDINGS LLC; ALTOR BIOSCIENCE, LLC; ETUBICS CORPORATION; IGDRASOL, INC.
To: INFINITY SA LLC, AS PURCHASER AGENT
Reel/Frame 066179/0074 →
Continuity (3)
Division
16639526
Provisional Application
62545744
· Aug 15, 2017
References Cited (95)
US 7387771B1
· Kratz
· 2008
[cited by applicant]
US 7902144B2
· Kratz
· 2011
[cited by applicant]
US 8153581B2
· Kratz
· 2012
[cited by applicant]
US 8846602B2
· Kratz
· 2014
[cited by applicant]
US 9623097B2
· Palena et al.
· 2017
[cited by applicant]
US 20150342975A1
· Geyer et al.
· 2015
[cited by applicant]
US 20180222982A1
· Dranoff
· 2018
[cited by examiner]
US 20190134174A1
· Jones
· 2019
[cited by examiner]
AU 2018318125A1
· 2020
[cited by applicant]
CA 3073045A1
· 2019
[cited by applicant]
CN 110996991A
· 2020
[cited by applicant]
EP 3668538A1
· 2020
[cited by applicant]
JP 2020531437A
· 2020
[cited by applicant]
KR 1020200033351A
· 2020
[cited by applicant]
KR 1020220068272A
· 2022
[cited by applicant]
WO 2016160602A2
· 2016
[cited by applicant]
WO 2016172249A1
· 2016
[cited by applicant]
WO 2016205738A2
· 2016
[cited by applicant]
WO 2017100709A1
· 2017
[cited by applicant]
WO 2018209208A1
· 2018
[cited by applicant]
WO 2019036485A1
· 2019
[cited by applicant]
WO 2019050926A1
· 2019
[cited by applicant]
Chawla et al (JAMA Oncology, 2015, 1:1272-1280) (IDS).
[cited by examiner]
Eilber et al (Journal of Clinical Oncology, May 30, 2017, 35, No. 15_suppl, abstract 11051) (IDS).
[cited by examiner]
Mita et al (Invest New Drugs, 2015, 33:341-348) (IDS).
[cited by examiner]
Chawla et al (JAMA Oncology, 2015, 1:1272-1280).
[cited by examiner]
Eilber et al (Journal of Clinical Oncology, May 30, 2017, 35, No. 15_suppl, abstract 11051).
[cited by examiner]
Mita et al (Invest New Drugs, 2015, 33:341-348).
[cited by examiner]
Jochems et al (Oncotarget, 2016, 7:86359-86373).
[cited by examiner]
Fiedler et al (2016). mRNA Cancer Vaccines, p. 61-85. In: Walther, W. (eds) Current Strategies in Cancer Gene Therapy. Recent Results in Cancer Research, vol. 209. Springer, Cham.
[cited by examiner]
Notification of Reason for Refusal received for Korean Patent Application Serial No. 10-2022-7016167 dated Jun. 14, 2022, 11 pages. (Including English Translation).
[cited by applicant]
Szczepanski et al., “Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors”, Cancer Immunol Immunother, Springer, vol. 59, No. …
[cited by applicant]
Notice of Allowance received for U.S. Appl. No. 16/639,526 dated Aug. 2, 2022, 21 pages.
[cited by applicant]
Notification of Final Rejection received for Korean Patent Application Serial No. 10-2022-7016167 dated Jan. 12, 2023, 7 pages. (Including English Translation).
[cited by applicant]
Notification of Final Rejection received for Korean Patent Application Serial No. 10-2022-7016167 dated Apr. 24, 2023, 7 pages. (Including English Translation).
[cited by applicant]
First Office Action received for the Chinese Patent Application Serial No. 201880053244.2 dated Feb. 18, 2023, 21 pages. (Including English Translation).
[cited by applicant]
Felices et al., “IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer”, Gynecologic Oncology, vol. 145, No. 3, Jun. 2017, pp. 1-9.
[cited by applicant]
Office Action received for the Canadian Patent Application Serial No. 3,073,045 dated Dec. 15, 2022, 4 pages.
[cited by applicant]
Jochems et al., “An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele”, Oncotarget, 2016, vol. 7, No. 52, pp. 86359-86373 (Cited from Specification).
[cited by applicant]
Hui-Chou et al., “Short-term application of doxorubicin chemotherapy immunosuppressive side effects for composite issue allotransplantation”, Annals of Plastic Surgery, Feb. 2012, vol. 68, No. 2, pp. 215-221 (Cited from…
[cited by applicant]
International Search Report and Written Opinion received in PCT application Serial No. PCT/US2018/046735 dated Dec. 3, 2018, 14 pages.
[cited by applicant]
Cytrx Corporation, “CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic”, PRNewswire, URL: https://www.prnewswire.com/news-releases/cytrxcorpor…
[cited by applicant]
Martins Ines et al., “First Trial Assessing Engineered Natural Killer Cells in Cancer Patients to Begin Soon”, Immuno-oncolgynews, URL: https://immuno-oncologynews.com/2017/01/31/nantkwest-first-trial-assessing-engineer…
[cited by applicant]
Jochems et al., “ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody”, International Journal of Cancer, Aug. 1, 2017, vol. 141, No. 3, 22 pages.
[cited by applicant]
International Preliminary Report on Patentability received in PCT application Serial No. PCT/US2018/046735 dated Feb. 27, 2020, 9 pages.
[cited by applicant]
Alizadeh et al., “Doxorubicin Eliminates Myeloid-Derived Suppressor Cells and Enhances the Efficacy of Adoptive T Sell Transfer in Breast Cancer”, Cancer Research, Jan. 1, 2014, vol. 74, No. 1, 24 pages.
[cited by applicant]
Machiels et al., “Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor ImmuneResponse of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2/neu Tolerized Mice1”, Cance…
[cited by applicant]
Hannesdottir et al., “Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response”, European Journal of Immunilogy, 2013, vol. 43, pp. 2718-2729.
[cited by applicant]
Zhang et al., “Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity”, Frontiers Immunology, May …
[cited by applicant]
Park et al., “Doxorubicin enhances CD4+ T-cell immune responses by inducing expression of CD40 ligand and 4-1BB”, International Immunopharmacology, 2009, vol. 9, pp. 1530-1539.
[cited by applicant]
Genbler et al., “Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival”, Oncoimmu…
[cited by applicant]
Fujii et al., “A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity (ADCC) employing NK or high affinity NK (haNK) cells in combination with cetuximab”, Journal Neurosurg, Jul. 28, 2017, vo…
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3073045 dated Feb. 3, 2021, 7 pages.
[cited by applicant]
Examination Report No. 1 received for Australian Patent Application Serial No. 2018318125 dated Mar. 4, 2021, 5 pages.
[cited by applicant]
Restriction Requirement received for U.S. Appl. No. 16/639,526 dated Jun. 11, 2021, 9 pages.
[cited by applicant]
Notice of Reasons for Refusal received for Japanese Patent Application Serial No. 2020508476 dated Apr. 27, 2021, 8 pages (Including English Translation).
[cited by applicant]
Gabitzsch et al., “The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic”, Oncotarget, 2015, vol. 6, No. 31, pp. 31344-31359.
[cited by applicant]
Pinette et al., “An IL-15-based super agonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck”, Cancer Immunology and Immunotherapy, 2019, 11 pages.
[cited by applicant]
Extended European Search Report received for European Patent Application Serial No. 18846765.8 dated May 19, 2021, 9 pages.
[cited by applicant]
Seery et al., “NANT cancer vaccine an orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer”, J…
[cited by applicant]
Examination Report No. 2 received for Australian Patent Application Serial No. 2018318125 dated May 20, 2021, 7 pages.
[cited by applicant]
Examination Report No. 3 received for Australian Patent Application Serial No. 2018318125 dated Jul. 29, 2021, 4 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/639,526 dated Aug. 23, 2021, 61 pages.
[cited by applicant]
Sharp et al (Biomedicines, 2016, 4:19, internet pp. 1-13).
[cited by applicant]
Foy et al (Cancer Immunology Immunotherapy, 2016, 65:537-549).
[cited by applicant]
Foy et al (PLoS ONE, 2016, 11:e0150084, internet pp. 1-18).
[cited by applicant]
Eralp et al (Breast Cancer Research, 2004, 6:R275-283).
[cited by applicant]
Wenneberg et al (Int. J. Cancer, 2013, 1643-1653).
[cited by applicant]
Yu et al (Clinical Cancer Research, 2010, 16:6019-6028).
[cited by applicant]
Klingemann et al (Frontiers in Immunology, 2016, 7:91, internet pp. 1-7).
[cited by applicant]
Van Audenaerde et al (Oncotarget, 2017, 8:56968-56979, published online May 25, 2017).
[cited by applicant]
Tonn et al (Cytotherapy, 2013, 15:1563-1570).
[cited by applicant]
Eureka Alert! Public Release (Jan. 14, 2016) (https://www.eurekalert.org/pub releases/2016-01/nnuos-nnlf011416.php).
[cited by applicant]
Biospace.com (Apr. 11, 2016) (https://www.biospace.com/article/releases/altor-bioscience-corporation-partners-with-the-nci-to-further-develop-b-altor-s-b-alt-803-and-alt-801-cancer-innnnunotherapeutics-/).
[cited by applicant]
Notice of Reasons for Refusal received for Korean Patent Application Serial No. 1020207007502 dated Aug. 18, 2021, 14 pages.(Including English Translation).
[cited by applicant]
Rapoport et al., “Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer”, Nature Medicine, 2005, vol. 11, No. 11, pp. 1230-1237.
[cited by applicant]
Rapoport et al., “Supplementary drawing of Restoration of immunity in lymphopenic individuals with cancer byvaccination and adoptive T-cell transfer”, Nature Medicine, 2005, vol. 11, No. 11, 1 page.
[cited by applicant]
Notice of Acceptance received for Australian Patent Application Serial No. 2018318125 dated Aug. 31, 2021, 3 pages.
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/639,526 dated Dec. 16, 2021, 22 pages.
[cited by applicant]
Non-Final Office Action received for U.S. Appl. No. 16/639,526 dated Feb. 2, 2022, 17 pages.
[cited by applicant]
Office Action received for Canadian Patent Application Serial No. 3,073,045 dated Feb. 22, 2022, 4 pages.
[cited by applicant]
Decision to Grant a Patent received for Japanese Patent Application Serial No. 2020-508476 dated Apr. 1, 2022, 6 pages. (Including English Translation).
[cited by applicant]
Notification of Final Rejection received for Korean Patent Application Serial No. 10-2020-7007502 dated Feb. 23, 2022, 6 pages. (Including English Translation).
[cited by applicant]
Final Office Action received for U.S. Appl. No. 16/639,526 dated May 18, 2022, 51 pages.
[cited by applicant]
NCT03387111 QUILT 3.090 Clinical trial.gov, first posted Dec. 2017.
[cited by applicant]
Second Office Action received for Chinese Patent Application Serial No. 201880053244.2 dated Aug. 24, 2023, 18 pages. (Including English Translation).
[cited by applicant]
Notice of Final Rejection received for Korean Patent Application Serial No. 1020237025519 dated Dec. 26, 2024 06 pages.(Including English Translation).
[cited by applicant]
Request for the Submission of an Opinion received for Korean Patent Application Serial No. 1020237025519 dated Apr. 22, 2024, 09 pages.(Including English Translation).
[cited by applicant]
Communication pursuant to Article 94(3) EPC received for European Patent Application Serial No. 18846765.8 dated Jan. 31, 2024, 8 pages.
[cited by applicant]
Office Action received for the Canadian Patent Application Serial No. 3,073,045 dated Sep. 18, 2023, 4 pages.
[cited by applicant]
Ash, A. (Feb. 2017) “Using a novel interluekin-15 construct (ALT-803) to enhance natural killer cell activity against cetuximab-treated head and neck cancer cells.” Annals of Surgical Oncology, vol. 24, No. 1, Supp. Sup…
[cited by applicant]
Notice of Final Rejection received in Korean Patent Application No. 10-2023-7025519, dated Oct. 24, 2025, 7 pages including English translation.
[cited by applicant]